ID   G3P_HUMAN               Reviewed;         335 AA.
AC   P04406; E7EUT4; P00354; Q53X65;
DT   21-JUL-1986, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 3.
DT   18-JUN-2025, entry version 278.
DE   RecName: Full=Glyceraldehyde-3-phosphate dehydrogenase {ECO:0000303|PubMed:6096136};
DE            Short=GAPDH {ECO:0000303|PubMed:2987855};
DE            EC=1.2.1.12 {ECO:0000269|PubMed:3170585};
DE   AltName: Full=Peptidyl-cysteine S-nitrosylase GAPDH {ECO:0000305};
DE            EC=2.6.99.- {ECO:0000250|UniProtKB:P04797};
GN   Name=GAPDH {ECO:0000303|PubMed:2987855, ECO:0000312|HGNC:HGNC:4141};
GN   Synonyms=GAPD {ECO:0000303|PubMed:6096136};
GN   ORFNames=CDABP0047, OK/SW-cl.12;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=6096136; DOI=10.1002/j.1460-2075.1984.tb02185.x;
RA   Hanauer A., Mandel J.-L.;
RT   "The glyceraldehyde 3 phosphate dehydrogenase gene family: structure of a
RT   human cDNA and of an X chromosome linked pseudogene; amazing complexity of
RT   the gene family in mouse.";
RL   EMBO J. 3:2627-2633(1984).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=6096821; DOI=10.1093/nar/12.23.9179;
RA   Arcari P., Martinelli R., Salvatore F.;
RT   "The complete sequence of a full length cDNA for human liver
RT   glyceraldehyde-3-phosphate dehydrogenase: evidence for multiple mRNA
RT   species.";
RL   Nucleic Acids Res. 12:9179-9189(1984).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Liver;
RX   PubMed=2987855; DOI=10.1093/nar/13.7.2485;
RA   Tso J.Y., Sun X.-H., Kao T.-H., Reece K.S., Wu R.;
RT   "Isolation and characterization of rat and human glyceraldehyde-3-phosphate
RT   dehydrogenase cDNAs: genomic complexity and molecular evolution of the
RT   gene.";
RL   Nucleic Acids Res. 13:2485-2502(1985).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Lung;
RX   PubMed=3664468;
RA   Tokunaga K., Nakamura Y., Sakata K., Fujimori K., Ohkubo M., Sawada K.,
RA   Sakiyama S.;
RT   "Enhanced expression of a glyceraldehyde-3-phosphate dehydrogenase gene in
RT   human lung cancers.";
RL   Cancer Res. 47:5616-5619(1987).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=3027061; DOI=10.1016/s0021-9258(19)75833-5;
RA   Allen R.W., Trach K.A., Hoch J.A.;
RT   "Identification of the 37-kDa protein displaying a variable interaction
RT   with the erythroid cell membrane as glyceraldehyde-3-phosphate
RT   dehydrogenase.";
RL   J. Biol. Chem. 262:649-653(1987).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=3170585; DOI=10.1016/s0021-9258(19)37593-3;
RA   Ercolani L., Florence B., Denaro M., Alexander M.;
RT   "Isolation and complete sequence of a functional human glyceraldehyde-3-
RT   phosphate dehydrogenase gene.";
RL   J. Biol. Chem. 263:15335-15341(1988).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Placenta;
RX   PubMed=1924305; DOI=10.1073/pnas.88.19.8460;
RA   Meyer-Siegler K., Mauro D.J., Seal G., Wurzer J., Deriel J.K.,
RA   Sirover M.A.;
RT   "A human nuclear uracil DNA glycosylase is the 37-kDa subunit of
RT   glyceraldehyde-3-phosphate dehydrogenase.";
RL   Proc. Natl. Acad. Sci. U.S.A. 88:8460-8464(1991).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Astrocytoma;
RX   PubMed=10944468; DOI=10.1006/bbrc.2000.3282;
RA   Ye Z., Connor J.R.;
RT   "cDNA cloning by amplification of circularized first strand cDNAs reveals
RT   non-IRE-regulated iron-responsive mRNAs.";
RL   Biochem. Biophys. Res. Commun. 275:223-227(2000).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Leukemia;
RA   Zhou J., Yu W., Tang H., Mei G., Tsang Y.T.M., Bouck J., Gibbs R.A.,
RA   Margolin J.F.;
RT   "Pediatric leukemia cDNA sequencing project.";
RL   Submitted (JUL-2000) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Colon adenocarcinoma;
RA   Shichijo S., Itoh K.;
RT   "Identification of immuno-peptidmics that are recognized by tumor-reactive
RT   CTL generated from TIL of colon cancer patients.";
RL   Submitted (MAY-2001) to the EMBL/GenBank/DDBJ databases.
RN   [11]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor vector.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [12]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT GLY-22.
RG   NIEHS SNPs program;
RL   Submitted (JUL-2003) to the EMBL/GenBank/DDBJ databases.
RN   [13]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.;
RT   "Cloning of human full open reading frames in Gateway(TM) system entry
RT   vector (pDONR201).";
RL   Submitted (MAY-2004) to the EMBL/GenBank/DDBJ databases.
RN   [14]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16541075; DOI=10.1038/nature04569;
RA   Scherer S.E., Muzny D.M., Buhay C.J., Chen R., Cree A., Ding Y.,
RA   Dugan-Rocha S., Gill R., Gunaratne P., Harris R.A., Hawes A.C.,
RA   Hernandez J., Hodgson A.V., Hume J., Jackson A., Khan Z.M., Kovar-Smith C.,
RA   Lewis L.R., Lozado R.J., Metzker M.L., Milosavljevic A., Miner G.R.,
RA   Montgomery K.T., Morgan M.B., Nazareth L.V., Scott G., Sodergren E.,
RA   Song X.-Z., Steffen D., Lovering R.C., Wheeler D.A., Worley K.C., Yuan Y.,
RA   Zhang Z., Adams C.Q., Ansari-Lari M.A., Ayele M., Brown M.J., Chen G.,
RA   Chen Z., Clerc-Blankenburg K.P., Davis C., Delgado O., Dinh H.H.,
RA   Draper H., Gonzalez-Garay M.L., Havlak P., Jackson L.R., Jacob L.S.,
RA   Kelly S.H., Li L., Li Z., Liu J., Liu W., Lu J., Maheshwari M.,
RA   Nguyen B.-V., Okwuonu G.O., Pasternak S., Perez L.M., Plopper F.J.H.,
RA   Santibanez J., Shen H., Tabor P.E., Verduzco D., Waldron L., Wang Q.,
RA   Williams G.A., Zhang J., Zhou J., Allen C.C., Amin A.G., Anyalebechi V.,
RA   Bailey M., Barbaria J.A., Bimage K.E., Bryant N.P., Burch P.E.,
RA   Burkett C.E., Burrell K.L., Calderon E., Cardenas V., Carter K., Casias K.,
RA   Cavazos I., Cavazos S.R., Ceasar H., Chacko J., Chan S.N., Chavez D.,
RA   Christopoulos C., Chu J., Cockrell R., Cox C.D., Dang M., Dathorne S.R.,
RA   David R., Davis C.M., Davy-Carroll L., Deshazo D.R., Donlin J.E.,
RA   D'Souza L., Eaves K.A., Egan A., Emery-Cohen A.J., Escotto M., Flagg N.,
RA   Forbes L.D., Gabisi A.M., Garza M., Hamilton C., Henderson N.,
RA   Hernandez O., Hines S., Hogues M.E., Huang M., Idlebird D.G., Johnson R.,
RA   Jolivet A., Jones S., Kagan R., King L.M., Leal B., Lebow H., Lee S.,
RA   LeVan J.M., Lewis L.C., London P., Lorensuhewa L.M., Loulseged H.,
RA   Lovett D.A., Lucier A., Lucier R.L., Ma J., Madu R.C., Mapua P.,
RA   Martindale A.D., Martinez E., Massey E., Mawhiney S., Meador M.G.,
RA   Mendez S., Mercado C., Mercado I.C., Merritt C.E., Miner Z.L., Minja E.,
RA   Mitchell T., Mohabbat F., Mohabbat K., Montgomery B., Moore N., Morris S.,
RA   Munidasa M., Ngo R.N., Nguyen N.B., Nickerson E., Nwaokelemeh O.O.,
RA   Nwokenkwo S., Obregon M., Oguh M., Oragunye N., Oviedo R.J., Parish B.J.,
RA   Parker D.N., Parrish J., Parks K.L., Paul H.A., Payton B.A., Perez A.,
RA   Perrin W., Pickens A., Primus E.L., Pu L.-L., Puazo M., Quiles M.M.,
RA   Quiroz J.B., Rabata D., Reeves K., Ruiz S.J., Shao H., Sisson I.,
RA   Sonaike T., Sorelle R.P., Sutton A.E., Svatek A.F., Svetz L.A.,
RA   Tamerisa K.S., Taylor T.R., Teague B., Thomas N., Thorn R.D., Trejos Z.Y.,
RA   Trevino B.K., Ukegbu O.N., Urban J.B., Vasquez L.I., Vera V.A.,
RA   Villasana D.M., Wang L., Ward-Moore S., Warren J.T., Wei X., White F.,
RA   Williamson A.L., Wleczyk R., Wooden H.S., Wooden S.H., Yen J., Yoon L.,
RA   Yoon V., Zorrilla S.E., Nelson D., Kucherlapati R., Weinstock G.,
RA   Gibbs R.A.;
RT   "The finished DNA sequence of human chromosome 12.";
RL   Nature 440:346-351(2006).
RN   [15]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [16]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Eye, Kidney, Lung, Lymph, and Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [17]
RP   PRELIMINARY PROTEIN SEQUENCE OF 2-335.
RC   TISSUE=Muscle;
RX   PubMed=7030790; DOI=10.1016/0014-5793(81)80587-x;
RA   Nowak K., Wolny M., Banas T.;
RT   "The complete amino acid sequence of human muscle glyceraldehyde 3-
RT   phosphate dehydrogenase.";
RL   FEBS Lett. 134:143-146(1981).
RN   [18]
RP   PROTEIN SEQUENCE OF 2-13.
RC   TISSUE=Platelet;
RX   PubMed=12665801; DOI=10.1038/nbt810;
RA   Gevaert K., Goethals M., Martens L., Van Damme J., Staes A., Thomas G.R.,
RA   Vandekerckhove J.;
RT   "Exploring proteomes and analyzing protein processing by mass spectrometric
RT   identification of sorted N-terminal peptides.";
RL   Nat. Biotechnol. 21:566-569(2003).
RN   [19]
RP   PROTEIN SEQUENCE OF 2-13; 62-84; 118-139; 198-215; 220-227; 235-248 AND
RP   310-335, CLEAVAGE OF INITIATOR METHIONINE, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY.
RC   TISSUE=Prostatic carcinoma;
RA   Bienvenut W.V., Gao M., Leug H.;
RL   Submitted (JUL-2009) to UniProtKB.
RN   [20]
RP   PROTEIN SEQUENCE OF 67-80; 87-107; 119-139; 146-186; 201-215; 235-248 AND
RP   310-334, AND IDENTIFICATION BY MASS SPECTROMETRY.
RC   TISSUE=Brain, Cajal-Retzius cell, and Fetal brain cortex;
RA   Lubec G., Vishwanath V., Chen W.-Q., Sun Y.;
RL   Submitted (DEC-2008) to UniProtKB.
RN   [21]
RP   PROTEIN SEQUENCE OF 220-226 AND 242-246.
RC   TISSUE=Heart;
RX   PubMed=7498159; DOI=10.1002/elps.11501601192;
RA   Kovalyov L.I., Shishkin S.S., Efimochkin A.S., Kovalyova M.A.,
RA   Ershova E.S., Egorov T.A., Musalyamov A.K.;
RT   "The major protein expression profile and two-dimensional protein database
RT   of human heart.";
RL   Electrophoresis 16:1160-1169(1995).
RN   [22]
RP   PARTIAL PROTEIN SEQUENCE.
RC   TISSUE=Muscle;
RX   PubMed=1193541;
RA   Nowak K., Kuczek M., Ostropolska L., Malarska A., Wolny M., Branowski T.;
RT   "The covalent structure of glyceraldehyde-phosphate dehydrogenase from
RT   human muscles. Isolation and amino acid sequences of peptides from tryptic
RT   digest.";
RL   Hoppe-Seyler's Z. Physiol. Chem. 356:1181-1183(1975).
RN   [23]
RP   FUNCTION, AND INTERACTION WITH PRKCI.
RX   PubMed=11724794; DOI=10.1074/jbc.m109744200;
RA   Tisdale E.J.;
RT   "Glyceraldehyde-3-phosphate dehydrogenase is phosphorylated by protein
RT   kinase Ciota /lambda and plays a role in microtubule dynamics in the early
RT   secretory pathway.";
RL   J. Biol. Chem. 277:3334-3341(2002).
RN   [24]
RP   SUBCELLULAR LOCATION.
RX   PubMed=12829261; DOI=10.1016/s0304-4165(03)00117-x;
RA   Mazzola J.L., Sirover M.A.;
RT   "Subcellular localization of human glyceraldehyde-3-phosphate dehydrogenase
RT   is independent of its glycolytic function.";
RL   Biochim. Biophys. Acta 1622:50-56(2003).
RN   [25]
RP   IDENTIFICATION BY MASS SPECTROMETRY.
RC   TISSUE=Lymphoblast;
RX   PubMed=14654843; DOI=10.1038/nature02166;
RA   Andersen J.S., Wilkinson C.J., Mayor T., Mortensen P., Nigg E.A., Mann M.;
RT   "Proteomic characterization of the human centrosome by protein correlation
RT   profiling.";
RL   Nature 426:570-574(2003).
RN   [26]
RP   IDENTIFICATION IN THE GAIT COMPLEX.
RX   PubMed=15479637; DOI=10.1016/j.cell.2004.09.030;
RA   Sampath P., Mazumder B., Seshadri V., Gerber C.A., Chavatte L., Kinter M.,
RA   Ting S.M., Dignam J.D., Kim S., Driscoll D.M., Fox P.L.;
RT   "Noncanonical function of glutamyl-prolyl-tRNA synthetase: gene-specific
RT   silencing of translation.";
RL   Cell 119:195-208(2004).
RN   [27]
RP   INTERACTION WITH WARS1.
RX   PubMed=15628863; DOI=10.1021/bi048313k;
RA   Wakasugi K., Nakano T., Morishima I.;
RT   "Oxidative stress-responsive intracellular regulation specific for the
RT   angiostatic form of human tryptophanyl-tRNA synthetase.";
RL   Biochemistry 44:225-232(2005).
RN   [28]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-42, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=15592455; DOI=10.1038/nbt1046;
RA   Rush J., Moritz A., Lee K.A., Guo A., Goss V.L., Spek E.J., Zhang H.,
RA   Zha X.-M., Polakiewicz R.D., Comb M.J.;
RT   "Immunoaffinity profiling of tyrosine phosphorylation in cancer cells.";
RL   Nat. Biotechnol. 23:94-101(2005).
RN   [29]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-83, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in signaling
RT   networks.";
RL   Cell 127:635-648(2006).
RN   [30]
RP   INTERACTION WITH USP25.
RX   PubMed=16501887; DOI=10.1007/s00018-005-5533-1;
RA   Bosch-Comas A., Lindsten K., Gonzalez-Duarte R., Masucci M.G., Marfany G.;
RT   "The ubiquitin-specific protease USP25 interacts with three sarcomeric
RT   proteins.";
RL   Cell. Mol. Life Sci. 63:723-734(2006).
RN   [31]
RP   ISGYLATION.
RX   PubMed=16815975; DOI=10.1073/pnas.0600397103;
RA   Wong J.J., Pung Y.F., Sze N.S., Chin K.C.;
RT   "HERC5 is an IFN-induced HECT-type E3 protein ligase that mediates type I
RT   IFN-induced ISGylation of protein targets.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:10735-10740(2006).
RN   [32]
RP   PHOSPHORYLATION AT THR-75; SER-122; SER-148; THR-229; THR-237 AND SER-312,
RP   DEAMIDATION AT ASN-9; ASN-64; ASN-70; ASN-149; ASN-155; ASN-225 AND
RP   ASN-316, AND METHYLATION AT LYS-5; LYS-66; LYS-194; LYS-215; LYS-227;
RP   LYS-260; LYS-263 AND LYS-334.
RX   PubMed=18183946; DOI=10.1021/pr700657y;
RA   Seo J., Jeong J., Kim Y.M., Hwang N., Paek E., Lee K.-J.;
RT   "Strategy for comprehensive identification of post-translational
RT   modifications in cellular proteins, including low abundant modifications:
RT   application to glyceraldehyde-3-phosphate dehydrogenase.";
RL   J. Proteome Res. 7:587-602(2008).
RN   [33]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-83; SER-151 AND THR-184, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [34]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [35]
RP   INTERACTION WITH FKBP6.
RX   PubMed=19001379; DOI=10.1074/jbc.m709779200;
RA   Jarczowski F., Jahreis G., Erdmann F., Schierhorn A., Fischer G.,
RA   Edlich F.;
RT   "FKBP36 is an inherent multifunctional glyceraldehyde-3-phosphate
RT   dehydrogenase inhibitor.";
RL   J. Biol. Chem. 284:766-773(2009).
RN   [36]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-184; THR-211 AND SER-312, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [37]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-61; LYS-194; LYS-219; LYS-227 AND
RP   LYS-254, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C.,
RA   Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [38]
RP   INTERACTION WITH EIF1AD.
RX   PubMed=20644585; DOI=10.1134/s1068162010030027;
RA   Rakitina T.V., Bogatova O.V., Smirnova E.V., Pozdeev V.I., Kostanian I.A.,
RA   Lipkin V.M.;
RT   "Haponin (eIF1AD) interacts with glyceraldehyde 3-phosphate dehydrogenase
RT   in the CHO-K1 cell line.";
RL   Bioorg. Khim. 36:312-318(2010).
RN   [39]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-75; SER-83 AND THR-184, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [40]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [41]
RP   MALONYLATION AT LYS-194 AND LYS-215.
RX   PubMed=21908771; DOI=10.1074/mcp.m111.012658;
RA   Peng C., Lu Z., Xie Z., Cheng Z., Chen Y., Tan M., Luo H., Zhang Y., He W.,
RA   Yang K., Zwaans B.M., Tishkoff D., Ho L., Lombard D., He T.C., Dai J.,
RA   Verdin E., Ye Y., Zhao Y.;
RT   "The first identification of lysine malonylation substrates and its
RT   regulatory enzyme.";
RL   Mol. Cell. Proteomics 10:M111.012658.01-M111.012658.12(2011).
RN   [42]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-83, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [43]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22905912; DOI=10.1021/pr300539b;
RA   Rosenow A., Noben J.P., Jocken J., Kallendrusch S., Fischer-Posovszky P.,
RA   Mariman E.C., Renes J.;
RT   "Resveratrol-induced changes of the human adipocyte secretion profile.";
RL   J. Proteome Res. 11:4733-4743(2012).
RN   [44]
RP   INTERACTION WITH RPL13A, AND S-NITROSYLATION AT CYS-247.
RX   PubMed=22771119; DOI=10.1016/j.molcel.2012.06.006;
RA   Jia J., Arif A., Willard B., Smith J.D., Stuehr D.J., Hazen S.L., Fox P.L.;
RT   "Protection of extraribosomal RPL13a by GAPDH and dysregulation by S-
RT   nitrosylation.";
RL   Mol. Cell 47:656-663(2012).
RN   [45]
RP   FUNCTION, AND RECONSTITUTION OF THE GAIT COMPLEX.
RX   PubMed=23071094; DOI=10.1128/mcb.01168-12;
RA   Arif A., Chatterjee P., Moodt R.A., Fox P.L.;
RT   "Heterotrimeric GAIT complex drives transcript-selective translation
RT   inhibition in murine macrophages.";
RL   Mol. Cell. Biol. 32:5046-5055(2012).
RN   [46]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E.,
RA   Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-terminal
RT   acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [47]
RP   FUNCTION, GLYCOSYLATION (MICROBIAL INFECTION), INTERACTION WITH TRAF2, AND
RP   MUTAGENESIS OF CYS-152; THR-211; THR-229; SER-241; THR-246 AND THR-277.
RX   PubMed=23332158; DOI=10.1016/j.chom.2012.11.010;
RA   Gao X., Wang X., Pham T.H., Feuerbacher L.A., Lubos M.L., Huang M.,
RA   Olsen R., Mushegian A., Slawson C., Hardwidge P.R.;
RT   "NleB, a bacterial effector with glycosyltransferase activity, targets
RT   GAPDH function to inhibit NF-kappaB activation.";
RL   Cell Host Microbe 13:87-99(2013).
RN   [48]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-83; SER-151; THR-153; THR-229
RP   AND SER-333, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [49]
RP   S-NITROSYLATION AT CYS-247, MUTAGENESIS OF LEU-245 AND GLU-250, AND DOMAIN.
RX   PubMed=25417112; DOI=10.1016/j.cell.2014.09.032;
RA   Jia J., Arif A., Terenzi F., Willard B., Plow E.F., Hazen S.L., Fox P.L.;
RT   "Target-selective protein S-nitrosylation by sequence motif recognition.";
RL   Cell 159:623-634(2014).
RN   [50]
RP   MECHANISM OF FREE RADICAL-INDUCED AGGREGATION, ACTIVE SITE, OXIDATION AT
RP   MET-46, AND MUTAGENESIS OF MET-46; MET-105; CYS-152; CYS-156; TRP-196;
RP   CYS-247 AND TYR-320.
RX   PubMed=25086035; DOI=10.1074/jbc.m114.570275;
RA   Samson A.L., Knaupp A.S., Kass I., Kleifeld O., Marijanovic E.M.,
RA   Hughes V.A., Lupton C.J., Buckle A.M., Bottomley S.P., Medcalf R.L.;
RT   "Oxidation of an exposed methionine instigates the aggregation of
RT   glyceraldehyde-3-phosphate dehydrogenase.";
RL   J. Biol. Chem. 289:26922-26936(2014).
RN   [51]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-177; THR-182; THR-184 AND
RP   SER-241, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [52]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M., Ayoub D.,
RA   Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [53]
RP   FUNCTION, GLYCOSYLATION (MICROBIAL INFECTION), INTERACTION WITH TRAF2, AND
RP   MUTAGENESIS OF CYS-152.
RX   PubMed=27387501; DOI=10.1074/jbc.m116.738278;
RA   Gao X., Pham T.H., Feuerbacher L.A., Chen K., Hays M.P., Singh G.,
RA   Rueter C., Hurtado-Guerrero R., Hardwidge P.R.;
RT   "Citrobacter rodentium NleB protein inhibits tumor necrosis factor (TNF)
RT   receptor-associated factor 3 (TRAF3) ubiquitination to reduce host type I
RT   interferon production.";
RL   J. Biol. Chem. 291:18232-18238(2016).
RN   [54]
RP   GLYCOSYLATION AT ARG-197 AND ARG-200 (MICROBIAL INFECTION).
RX   PubMed=28522607; DOI=10.1074/jbc.m117.790675;
RA   El Qaidi S., Chen K., Halim A., Siukstaite L., Rueter C.,
RA   Hurtado-Guerrero R., Clausen H., Hardwidge P.R.;
RT   "NleB/SseK effectors from Citrobacter rodentium, Escherichia coli, and
RT   Salmonella enterica display distinct differences in host substrate
RT   specificity.";
RL   J. Biol. Chem. 292:11423-11430(2017).
RN   [55]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-186, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=28112733; DOI=10.1038/nsmb.3366;
RA   Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C.,
RA   Nielsen M.L.;
RT   "Site-specific mapping of the human SUMO proteome reveals co-modification
RT   with phosphorylation.";
RL   Nat. Struct. Mol. Biol. 24:325-336(2017).
RN   [56]
RP   X-RAY CRYSTALLOGRAPHY (3.5 ANGSTROMS).
RX   PubMed=957435; DOI=10.1016/0022-2836(76)90013-9;
RA   Mercer W.D., Winn S.I., Watson H.C.;
RT   "Twinning in crystals of human skeletal muscle D-glyceraldehyde-3-phosphate
RT   dehydrogenase.";
RL   J. Mol. Biol. 104:277-283(1976).
RN   [57]
RP   X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) IN COMPLEX WITH NAD, AND SUBUNIT.
RX   PubMed=16239728; DOI=10.1107/s0907444905026740;
RA   Ismail S.A., Park H.W.;
RT   "Structural analysis of human liver glyceraldehyde-3-phosphate
RT   dehydrogenase.";
RL   Acta Crystallogr. D 61:1508-1513(2005).
RN   [58]
RP   X-RAY CRYSTALLOGRAPHY (1.75 ANGSTROMS) IN COMPLEX WITH NAD, AND SUBUNIT.
RX   PubMed=16510976; DOI=10.1107/s0907444905042289;
RA   Jenkins J.L., Tanner J.J.;
RT   "High-resolution structure of human D-glyceraldehyde-3-phosphate
RT   dehydrogenase.";
RL   Acta Crystallogr. D 62:290-301(2006).
CC   -!- FUNCTION: Has both glyceraldehyde-3-phosphate dehydrogenase and
CC       nitrosylase activities, thereby playing a role in glycolysis and
CC       nuclear functions, respectively (PubMed:11724794, PubMed:3170585).
CC       Glyceraldehyde-3-phosphate dehydrogenase is a key enzyme in glycolysis
CC       that catalyzes the first step of the pathway by converting D-
CC       glyceraldehyde 3-phosphate (G3P) into 3-phospho-D-glyceroyl phosphate
CC       (PubMed:11724794, PubMed:3170585). Modulates the organization and
CC       assembly of the cytoskeleton (By similarity). Facilitates the CHP1-
CC       dependent microtubule and membrane associations through its ability to
CC       stimulate the binding of CHP1 to microtubules (By similarity).
CC       Component of the GAIT (gamma interferon-activated inhibitor of
CC       translation) complex which mediates interferon-gamma-induced
CC       transcript-selective translation inhibition in inflammation processes
CC       (PubMed:23071094). Upon interferon-gamma treatment assembles into the
CC       GAIT complex which binds to stem loop-containing GAIT elements in the
CC       3'-UTR of diverse inflammatory mRNAs (such as ceruplasmin) and
CC       suppresses their translation (PubMed:23071094). Also plays a role in
CC       innate immunity by promoting TNF-induced NF-kappa-B activation and type
CC       I interferon production, via interaction with TRAF2 and TRAF3,
CC       respectively (PubMed:23332158, PubMed:27387501). Participates in
CC       nuclear events including transcription, RNA transport, DNA replication
CC       and apoptosis (By similarity). Nuclear functions are probably due to
CC       the nitrosylase activity that mediates cysteine S-nitrosylation of
CC       nuclear target proteins such as SIRT1, HDAC2 and PRKDC (By similarity).
CC       {ECO:0000250|UniProtKB:P04797, ECO:0000269|PubMed:11724794,
CC       ECO:0000269|PubMed:23071094, ECO:0000269|PubMed:23332158,
CC       ECO:0000269|PubMed:27387501, ECO:0000269|PubMed:3170585}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=D-glyceraldehyde 3-phosphate + phosphate + NAD(+) = (2R)-3-
CC         phospho-glyceroyl phosphate + NADH + H(+); Xref=Rhea:RHEA:10300,
CC         ChEBI:CHEBI:15378, ChEBI:CHEBI:43474, ChEBI:CHEBI:57540,
CC         ChEBI:CHEBI:57604, ChEBI:CHEBI:57945, ChEBI:CHEBI:59776; EC=1.2.1.12;
CC         Evidence={ECO:0000255|PROSITE-ProRule:PRU10009,
CC         ECO:0000269|PubMed:3170585};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=S-nitroso-L-cysteinyl-[GAPDH] + L-cysteinyl-[protein] = L-
CC         cysteinyl-[GAPDH] + S-nitroso-L-cysteinyl-[protein];
CC         Xref=Rhea:RHEA:66684, Rhea:RHEA-COMP:10131, Rhea:RHEA-COMP:17089,
CC         Rhea:RHEA-COMP:17090, Rhea:RHEA-COMP:17091, ChEBI:CHEBI:29950,
CC         ChEBI:CHEBI:149494; Evidence={ECO:0000250|UniProtKB:P04797};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:66685;
CC         Evidence={ECO:0000250|UniProtKB:P04797};
CC   -!- ACTIVITY REGULATION: Glyceraldehyde-3-phosphate dehydrogenase activity
CC       is inhibited by fumarate, via the formation of S-(2-succinyl)cysteine
CC       residues. {ECO:0000250|UniProtKB:P04797}.
CC   -!- PATHWAY: Carbohydrate degradation; glycolysis; pyruvate from D-
CC       glyceraldehyde 3-phosphate: step 1/5.
CC   -!- SUBUNIT: Homotetramer (PubMed:16239728, PubMed:16510976). Interacts
CC       with TPPP; the interaction is direct (By similarity). Interacts (when
CC       S-nitrosylated) with SIAH1; leading to nuclear translocation (By
CC       similarity). Interacts with RILPL1/GOSPEL, leading to prevent the
CC       interaction between GAPDH and SIAH1 and prevent nuclear translocation
CC       (By similarity). Interacts with CHP1; the interaction increases the
CC       binding of CHP1 with microtubules (By similarity). Associates with
CC       microtubules (By similarity). Interacts with EIF1AD, USP25, PRKCI and
CC       WARS1 (PubMed:11724794, PubMed:15628863, PubMed:16501887,
CC       PubMed:20644585). Interacts with phosphorylated RPL13A; inhibited by
CC       oxidatively-modified low-densitity lipoprotein (LDL(ox))
CC       (PubMed:22771119). Component of the GAIT complex (PubMed:15479637).
CC       Interacts with FKBP6; leading to inhibit GAPDH catalytic activity
CC       (PubMed:19001379). Interacts with TRAF2, promoting TRAF2 ubiquitination
CC       (PubMed:23332158). Interacts with TRAF3, promoting TRAF3 ubiquitination
CC       (PubMed:27387501). {ECO:0000250|UniProtKB:P04797,
CC       ECO:0000250|UniProtKB:P10096, ECO:0000269|PubMed:11724794,
CC       ECO:0000269|PubMed:15479637, ECO:0000269|PubMed:15628863,
CC       ECO:0000269|PubMed:16239728, ECO:0000269|PubMed:16501887,
CC       ECO:0000269|PubMed:16510976, ECO:0000269|PubMed:19001379,
CC       ECO:0000269|PubMed:20644585, ECO:0000269|PubMed:22771119,
CC       ECO:0000269|PubMed:23332158, ECO:0000269|PubMed:27387501}.
CC   -!- INTERACTION:
CC       P04406; Q6UY14-3: ADAMTSL4; NbExp=3; IntAct=EBI-354056, EBI-10173507;
CC       P04406; Q9UIJ7: AK3; NbExp=3; IntAct=EBI-354056, EBI-3916527;
CC       P04406; P05067: APP; NbExp=3; IntAct=EBI-354056, EBI-77613;
CC       P04406; Q9UQM7: CAMK2A; NbExp=3; IntAct=EBI-354056, EBI-1383687;
CC       P04406; Q14194: CRMP1; NbExp=3; IntAct=EBI-354056, EBI-473101;
CC       P04406; P35222: CTNNB1; NbExp=3; IntAct=EBI-354056, EBI-491549;
CC       P04406; Q9BPW9-4: DHRS9; NbExp=3; IntAct=EBI-354056, EBI-19157435;
CC       P04406; P00533: EGFR; NbExp=7; IntAct=EBI-354056, EBI-297353;
CC       P04406; O00471: EXOC5; NbExp=3; IntAct=EBI-354056, EBI-949824;
CC       P04406; O75344: FKBP6; NbExp=3; IntAct=EBI-354056, EBI-744771;
CC       P04406; P06241: FYN; NbExp=3; IntAct=EBI-354056, EBI-515315;
CC       P04406; P04406: GAPDH; NbExp=2; IntAct=EBI-354056, EBI-354056;
CC       P04406; O14556: GAPDHS; NbExp=3; IntAct=EBI-354056, EBI-1057431;
CC       P04406; Q8NEA9: GMCL2; NbExp=3; IntAct=EBI-354056, EBI-745707;
CC       P04406; P42858: HTT; NbExp=7; IntAct=EBI-354056, EBI-466029;
CC       P04406; Q92993-2: KAT5; NbExp=3; IntAct=EBI-354056, EBI-20795332;
CC       P04406; P42695: NCAPD3; NbExp=2; IntAct=EBI-354056, EBI-722805;
CC       P04406; P35228: NOS2; NbExp=8; IntAct=EBI-354056, EBI-6662224;
CC       P04406; P12004: PCNA; NbExp=3; IntAct=EBI-354056, EBI-358311;
CC       P04406; P00558: PGK1; NbExp=2; IntAct=EBI-354056, EBI-709599;
CC       P04406; P48147: PREP; NbExp=5; IntAct=EBI-354056, EBI-1049962;
CC       P04406; P17612: PRKACA; NbExp=3; IntAct=EBI-354056, EBI-476586;
CC       P04406; Q8WUY3: PRUNE2; NbExp=3; IntAct=EBI-354056, EBI-743880;
CC       P04406; Q9UHX1-2: PUF60; NbExp=3; IntAct=EBI-354056, EBI-11529177;
CC       P04406; P15927: RPA2; NbExp=2; IntAct=EBI-354056, EBI-621404;
CC       P04406; P05109: S100A8; NbExp=6; IntAct=EBI-354056, EBI-355281;
CC       P04406; Q96GZ6: SLC41A3; NbExp=3; IntAct=EBI-354056, EBI-7225508;
CC       P04406; P00441: SOD1; NbExp=3; IntAct=EBI-354056, EBI-990792;
CC       P04406; Q9BSI4: TINF2; NbExp=2; IntAct=EBI-354056, EBI-717399;
CC       P04406; P10599: TXN; NbExp=3; IntAct=EBI-354056, EBI-594644;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm, cytosol {ECO:0000269|PubMed:12829261}.
CC       Nucleus {ECO:0000250|UniProtKB:P04797}. Cytoplasm, perinuclear region
CC       {ECO:0000269|PubMed:12829261}. Membrane {ECO:0000269|PubMed:12829261}.
CC       Cytoplasm, cytoskeleton {ECO:0000250|UniProtKB:P04797}.
CC       Note=Translocates to the nucleus following S-nitrosylation and
CC       interaction with SIAH1, which contains a nuclear localization signal
CC       (By similarity). Postnuclear and Perinuclear regions (PubMed:12829261).
CC       {ECO:0000250|UniProtKB:P04797, ECO:0000269|PubMed:12829261}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P04406-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P04406-2; Sequence=VSP_047289;
CC   -!- DOMAIN: The [IL]-x-C-x-x-[DE] motif is a proposed target motif for
CC       cysteine S-nitrosylation mediated by the iNOS-S100A8/A9
CC       transnitrosylase complex. {ECO:0000305|PubMed:25417112}.
CC   -!- PTM: S-nitrosylation of Cys-152 leads to interaction with SIAH1,
CC       followed by translocation to the nucleus (By similarity). S-
CC       nitrosylation of Cys-247 is induced by interferon-gamma and LDL(ox)
CC       implicating the iNOS-S100A8/9 transnitrosylase complex and seems to
CC       prevent interaction with phosphorylated RPL13A and to interfere with
CC       GAIT complex activity (PubMed:22771119, PubMed:25417112).
CC       {ECO:0000250|UniProtKB:P04797, ECO:0000269|PubMed:22771119,
CC       ECO:0000269|PubMed:25417112}.
CC   -!- PTM: ISGylated. {ECO:0000305|PubMed:16815975}.
CC   -!- PTM: Sulfhydration at Cys-152 increases catalytic activity.
CC       {ECO:0000250|UniProtKB:P16858}.
CC   -!- PTM: Oxidative stress can promote the formation of high molecular
CC       weight disulfide-linked GAPDH aggregates, through a process called
CC       nucleocytoplasmic coagulation. Such aggregates can be observed in vivo
CC       in the affected tissues of patients with Alzheimer disease or alcoholic
CC       liver cirrhosis, or in cell cultures during necrosis. Oxidation at Met-
CC       46 may play a pivotal role in the formation of these insoluble
CC       structures. This modification has been detected in vitro following
CC       treatment with free radical donor (+/-)-(E)-4-ethyl-2-[(E)-
CC       hydroxyimino]-5-nitro-3-hexenamide. It has been proposed to destabilize
CC       nearby residues, increasing the likelihood of secondary oxidative
CC       damages, including oxidation of Tyr-45 and Met-105. This cascade of
CC       oxidations may augment GAPDH misfolding, leading to intermolecular
CC       disulfide cross-linking and aggregation. {ECO:0000305|PubMed:25086035}.
CC   -!- PTM: Succination of Cys-152 and Cys-247 by the Krebs cycle intermediate
CC       fumarate, which leads to S-(2-succinyl)cysteine residues, inhibits
CC       glyceraldehyde-3-phosphate dehydrogenase activity. Fumarate
CC       concentration as well as succination of cysteine residues in GAPDH is
CC       significantly increased in muscle of diabetic mammals. It was proposed
CC       that the S-(2-succinyl)cysteine chemical modification may be a useful
CC       biomarker of mitochondrial and oxidative stress in diabetes and that
CC       succination of GAPDH and other thiol proteins by fumarate may
CC       contribute to the metabolic changes underlying the development of
CC       diabetes complications. {ECO:0000250|UniProtKB:P04797}.
CC   -!- PTM: (Microbial infection) Glycosylated by C.rodentium protein NleB,
CC       enteropathogenic E.coli protein NleB1 and S.typhimurium protein Ssek1:
CC       arginine GlcNAcylation prevents the interaction with TRAF2 and TRAF3
CC       (PubMed:23332158, PubMed:27387501, PubMed:28522607). This leads to
CC       reduced ubiquitination of TRAF2 and TRAF3, and subsequent inhibition of
CC       NF-kappa-B signaling and type I interferon production, respectively
CC       (PubMed:23332158, PubMed:27387501). {ECO:0000269|PubMed:23332158,
CC       ECO:0000269|PubMed:27387501, ECO:0000269|PubMed:28522607}.
CC   -!- SIMILARITY: Belongs to the glyceraldehyde-3-phosphate dehydrogenase
CC       family. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Glyceraldehyde 3-phosphate
CC       dehydrogenase entry;
CC       URL="https://en.wikipedia.org/wiki/Glyceraldehyde_3-phosphate_dehydrogenase";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X01677; CAA25833.1; -; mRNA.
DR   EMBL; M17851; AAA86283.1; -; mRNA.
DR   EMBL; M33197; AAA52518.1; -; mRNA.
DR   EMBL; J02642; AAA52496.1; -; mRNA.
DR   EMBL; J04038; AAA53191.1; -; Genomic_DNA.
DR   EMBL; X53778; CAA37794.1; -; mRNA.
DR   EMBL; AF261085; AAF99678.1; -; mRNA.
DR   EMBL; AY007133; AAG01996.1; -; mRNA.
DR   EMBL; AB062273; BAB93466.1; -; mRNA.
DR   EMBL; BT006893; AAP35539.1; -; mRNA.
DR   EMBL; AY340484; AAP88932.1; -; Genomic_DNA.
DR   EMBL; CR407671; CAG28599.1; -; mRNA.
DR   EMBL; AC006064; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471116; EAW88787.1; -; Genomic_DNA.
DR   EMBL; BC001601; AAH01601.1; -; mRNA.
DR   EMBL; BC004109; AAH04109.1; -; mRNA.
DR   EMBL; BC009081; AAH09081.1; -; mRNA.
DR   EMBL; BC013310; AAH13310.1; -; mRNA.
DR   EMBL; BC023632; AAH23632.1; -; mRNA.
DR   EMBL; BC025925; AAH25925.1; -; mRNA.
DR   EMBL; BC026907; AAH26907.1; -; mRNA.
DR   EMBL; BC029618; AAH29618.1; -; mRNA.
DR   EMBL; BC083511; AAH83511.1; -; mRNA.
DR   CCDS; CCDS58201.1; -. [P04406-2]
DR   CCDS; CCDS8549.1; -. [P04406-1]
DR   PIR; A31988; DEHUG3.
DR   RefSeq; NP_001243728.1; NM_001256799.3. [P04406-2]
DR   RefSeq; NP_001276674.1; NM_001289745.3. [P04406-1]
DR   RefSeq; NP_001276675.1; NM_001289746.2. [P04406-1]
DR   RefSeq; NP_002037.2; NM_002046.5. [P04406-1]
DR   PDB; 1U8F; X-ray; 1.75 A; O/P/Q/R=1-335.
DR   PDB; 1ZNQ; X-ray; 2.50 A; O/P/Q/R=1-335.
DR   PDB; 3GPD; X-ray; 3.50 A; G/R=2-335.
DR   PDB; 4WNC; X-ray; 1.99 A; A/B/C/D/E/F/G/O=1-335.
DR   PDB; 4WNI; X-ray; 2.30 A; A/B/C/O=1-335.
DR   PDB; 6ADE; X-ray; 3.15 A; A/B/C=1-335.
DR   PDB; 6IQ6; X-ray; 2.29 A; A/B/C/D/E/F/G/H=1-335.
DR   PDB; 6M61; X-ray; 1.82 A; O/P/Q/R=1-335.
DR   PDB; 6YND; X-ray; 1.52 A; A/B/C/D/E/F/G/H=1-335.
DR   PDB; 6YNE; X-ray; 1.85 A; A/B/C/D=1-335.
DR   PDB; 6YNF; X-ray; 2.39 A; A/B/C/D/E/F/G/H=2-335.
DR   PDB; 6YNH; X-ray; 2.62 A; B/D/F/G=1-335.
DR   PDB; 8DNS; EM; 3.22 A; O/P/Q/R=1-335.
DR   PDB; 8G12; EM; 2.17 A; A/B/C/D=2-335.
DR   PDB; 8G13; EM; 2.30 A; A/B/C/D=2-335.
DR   PDB; 8G14; EM; 2.30 A; A/B/C/D=2-335.
DR   PDB; 8G15; EM; 2.07 A; A/B/C/D=2-335.
DR   PDB; 8G16; EM; 2.07 A; A/B/C/D=2-335.
DR   PDB; 8G17; EM; 1.98 A; A/B/C/D=2-335.
DR   PDB; 8P5F; X-ray; 1.82 A; AAA/DDD/EEE/GGG=1-335.
DR   PDBsum; 1U8F; -.
DR   PDBsum; 1ZNQ; -.
DR   PDBsum; 3GPD; -.
DR   PDBsum; 4WNC; -.
DR   PDBsum; 4WNI; -.
DR   PDBsum; 6ADE; -.
DR   PDBsum; 6IQ6; -.
DR   PDBsum; 6M61; -.
DR   PDBsum; 6YND; -.
DR   PDBsum; 6YNE; -.
DR   PDBsum; 6YNF; -.
DR   PDBsum; 6YNH; -.
DR   PDBsum; 8DNS; -.
DR   PDBsum; 8G12; -.
DR   PDBsum; 8G13; -.
DR   PDBsum; 8G14; -.
DR   PDBsum; 8G15; -.
DR   PDBsum; 8G16; -.
DR   PDBsum; 8G17; -.
DR   PDBsum; 8P5F; -.
DR   AlphaFoldDB; P04406; -.
DR   EMDB; EMD-27579; -.
DR   EMDB; EMD-29659; -.
DR   EMDB; EMD-29660; -.
DR   EMDB; EMD-29661; -.
DR   EMDB; EMD-29662; -.
DR   EMDB; EMD-29663; -.
DR   EMDB; EMD-29664; -.
DR   EMDB; EMD-32162; -.
DR   SMR; P04406; -.
DR   BioGRID; 108868; 735.
DR   ComplexPortal; CPX-2476; GAIT complex.
DR   CORUM; P04406; -.
DR   DIP; DIP-32521N; -.
DR   FunCoup; P04406; 1599.
DR   IntAct; P04406; 248.
DR   MINT; P04406; -.
DR   STRING; 9606.ENSP00000380070; -.
DR   BindingDB; P04406; -.
DR   ChEMBL; CHEMBL2284; -.
DR   DrugBank; DB07347; 4-(2-Aminoethyl)Benzenesulfonyl Fluoride.
DR   DrugBank; DB02059; Adenosine-5-Diphosphoribose.
DR   DrugBank; DB11638; Artenimol.
DR   DrugBank; DB09130; Copper.
DR   DrugBank; DB00157; NADH.
DR   DrugBank; DB12879; Omigapil.
DR   DrugBank; DB03893; Thionicotinamide-Adenine-Dinucleotide.
DR   DrugBank; DB09092; Xanthinol.
DR   DrugCentral; P04406; -.
DR   MoonDB; P04406; Curated.
DR   MoonProt; P04406; -.
DR   GlyConnect; 1941; 7 N-Linked glycans (2 sites).
DR   GlyCosmos; P04406; 6 sites, 9 glycans.
DR   GlyGen; P04406; 5 sites, 18 N-linked glycans (2 sites), 2 O-linked glycans (2 sites).
DR   iPTMnet; P04406; -.
DR   MetOSite; P04406; -.
DR   PhosphoSitePlus; P04406; -.
DR   SwissPalm; P04406; -.
DR   BioMuta; GAPDH; -.
DR   DMDM; 120649; -.
DR   OGP; P04406; -.
DR   REPRODUCTION-2DPAGE; IPI00219018; -.
DR   REPRODUCTION-2DPAGE; P04406; -.
DR   CPTAC; CPTAC-2733; -.
DR   CPTAC; CPTAC-5855; -.
DR   CPTAC; CPTAC-5880; -.
DR   CPTAC; CPTAC-5942; -.
DR   jPOST; P04406; -.
DR   MassIVE; P04406; -.
DR   PaxDb; 9606-ENSP00000229239; -.
DR   PeptideAtlas; P04406; -.
DR   PRIDE; P04406; -.
DR   ProteomicsDB; 18491; -.
DR   ProteomicsDB; 51703; -. [P04406-1]
DR   Pumba; P04406; -.
DR   TopDownProteomics; P04406-1; -. [P04406-1]
DR   ABCD; P04406; 1 sequenced antibody.
DR   Antibodypedia; 3923; 2683 antibodies from 59 providers.
DR   CPTC; P04406; 1 antibody.
DR   DNASU; 2597; -.
DR   Ensembl; ENST00000229239.10; ENSP00000229239.5; ENSG00000111640.15. [P04406-1]
DR   Ensembl; ENST00000396858.5; ENSP00000380067.1; ENSG00000111640.15. [P04406-2]
DR   Ensembl; ENST00000396859.5; ENSP00000380068.1; ENSG00000111640.15. [P04406-1]
DR   Ensembl; ENST00000396861.5; ENSP00000380070.1; ENSG00000111640.15. [P04406-1]
DR   Ensembl; ENST00000619601.1; ENSP00000478864.1; ENSG00000111640.15. [P04406-2]
DR   GeneID; 2597; -.
DR   KEGG; hsa:2597; -.
DR   MANE-Select; ENST00000229239.10; ENSP00000229239.5; NM_002046.7; NP_002037.2.
DR   UCSC; uc031qfw.3; human. [P04406-1]
DR   AGR; HGNC:4141; -.
DR   CTD; 2597; -.
DR   DisGeNET; 2597; -.
DR   GeneCards; GAPDH; -.
DR   HGNC; HGNC:4141; GAPDH.
DR   HPA; ENSG00000111640; Group enriched (skeletal muscle, tongue).
DR   MalaCards; GAPDH; -.
DR   MIM; 138400; gene.
DR   neXtProt; NX_P04406; -.
DR   OpenTargets; ENSG00000111640; -.
DR   PharmGKB; PA28554; -.
DR   VEuPathDB; HostDB:ENSG00000111640; -.
DR   eggNOG; KOG0657; Eukaryota.
DR   GeneTree; ENSGT00940000153298; -.
DR   HOGENOM; CLU_030140_0_3_1; -.
DR   InParanoid; P04406; -.
DR   OMA; YGYTCNM; -.
DR   OrthoDB; 9528699at2759; -.
DR   PAN-GO; P04406; 3 GO annotations based on evolutionary models.
DR   PhylomeDB; P04406; -.
DR   TreeFam; TF300533; -.
DR   BioCyc; MetaCyc:HS03433-MONOMER; -.
DR   BRENDA; 1.2.1.12; 2681.
DR   PathwayCommons; P04406; -.
DR   Reactome; R-HSA-70171; Glycolysis.
DR   Reactome; R-HSA-70263; Gluconeogenesis.
DR   SABIO-RK; P04406; -.
DR   SignaLink; P04406; -.
DR   SIGNOR; P04406; -.
DR   UniPathway; UPA00109; UER00184.
DR   BioGRID-ORCS; 2597; 626 hits in 1149 CRISPR screens.
DR   CD-CODE; 232F8A39; P-body.
DR   CD-CODE; 91857CE7; Nucleolus.
DR   CD-CODE; FB4E32DD; Presynaptic clusters and postsynaptic densities.
DR   ChiTaRS; GAPDH; human.
DR   EvolutionaryTrace; P04406; -.
DR   GeneWiki; Glyceraldehyde_3-phosphate_dehydrogenase; -.
DR   GenomeRNAi; 2597; -.
DR   Pharos; P04406; Tchem.
DR   PRO; PR:P04406; -.
DR   Proteomes; UP000005640; Chromosome 12.
DR   RNAct; P04406; protein.
DR   Bgee; ENSG00000111640; Expressed in frontal pole and 218 other cell types or tissues.
DR   ExpressionAtlas; P04406; baseline and differential.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0097452; C:GAIT complex; IDA:UniProtKB.
DR   GO; GO:0043231; C:intracellular membrane-bounded organelle; IDA:HPA.
DR   GO; GO:0005811; C:lipid droplet; IDA:UniProtKB.
DR   GO; GO:0016020; C:membrane; HDA:UniProtKB.
DR   GO; GO:0015630; C:microtubule cytoskeleton; ISS:UniProtKB.
DR   GO; GO:0031965; C:nuclear membrane; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:CACAO.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0005886; C:plasma membrane; IDA:HPA.
DR   GO; GO:1990904; C:ribonucleoprotein complex; IDA:UniProtKB.
DR   GO; GO:0031982; C:vesicle; HDA:UniProtKB.
DR   GO; GO:0019828; F:aspartic-type endopeptidase inhibitor activity; IDA:UniProtKB.
DR   GO; GO:0097718; F:disordered domain specific binding; IPI:CAFA.
DR   GO; GO:0004365; F:glyceraldehyde-3-phosphate dehydrogenase (NAD+) (phosphorylating) activity; ISS:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0008017; F:microtubule binding; ISS:UniProtKB.
DR   GO; GO:0051287; F:NAD binding; IEA:InterPro.
DR   GO; GO:0050661; F:NADP binding; IEA:InterPro.
DR   GO; GO:0035605; F:peptidyl-cysteine S-nitrosylase activity; ISS:UniProtKB.
DR   GO; GO:0061844; P:antimicrobial humoral immune response mediated by antimicrobial peptide; IDA:UniProtKB.
DR   GO; GO:0071346; P:cellular response to type II interferon; IDA:UniProtKB.
DR   GO; GO:0050832; P:defense response to fungus; IDA:UniProtKB.
DR   GO; GO:0006006; P:glucose metabolic process; IEA:InterPro.
DR   GO; GO:0006096; P:glycolytic process; IBA:GO_Central.
DR   GO; GO:0051873; P:killing by host of symbiont cells; IDA:UniProtKB.
DR   GO; GO:0031640; P:killing of cells of another organism; IDA:UniProtKB.
DR   GO; GO:0000226; P:microtubule cytoskeleton organization; ISS:UniProtKB.
DR   GO; GO:0010951; P:negative regulation of endopeptidase activity; IDA:UniProtKB.
DR   GO; GO:0017148; P:negative regulation of translation; IDA:UniProtKB.
DR   GO; GO:0051402; P:neuron apoptotic process; ISS:UniProtKB.
DR   GO; GO:0035606; P:peptidyl-cysteine S-trans-nitrosylation; ISS:UniProtKB.
DR   GO; GO:0043123; P:positive regulation of canonical NF-kappaB signal transduction; IDA:UniProtKB.
DR   GO; GO:0001819; P:positive regulation of cytokine production; IDA:UniProtKB.
DR   GO; GO:0032481; P:positive regulation of type I interferon production; IDA:UniProtKB.
DR   GO; GO:0050821; P:protein stabilization; ISS:UniProtKB.
DR   GO; GO:0016241; P:regulation of macroautophagy; TAS:ParkinsonsUK-UCL.
DR   CDD; cd18126; GAPDH_I_C; 1.
DR   CDD; cd05214; GAPDH_I_N; 1.
DR   FunFam; 3.30.360.10:FF:000001; Glyceraldehyde-3-phosphate dehydrogenase; 1.
DR   FunFam; 3.40.50.720:FF:001161; Glyceraldehyde-3-phosphate dehydrogenase; 1.
DR   Gene3D; 3.30.360.10; Dihydrodipicolinate Reductase, domain 2; 1.
DR   Gene3D; 3.40.50.720; NAD(P)-binding Rossmann-like Domain; 1.
DR   InterPro; IPR020831; GlycerAld/Erythrose_P_DH.
DR   InterPro; IPR020830; GlycerAld_3-P_DH_AS.
DR   InterPro; IPR020829; GlycerAld_3-P_DH_cat.
DR   InterPro; IPR020828; GlycerAld_3-P_DH_NAD(P)-bd.
DR   InterPro; IPR006424; Glyceraldehyde-3-P_DH_1.
DR   InterPro; IPR036291; NAD(P)-bd_dom_sf.
DR   NCBIfam; TIGR01534; GAPDH-I; 1.
DR   PANTHER; PTHR10836; GLYCERALDEHYDE 3-PHOSPHATE DEHYDROGENASE; 1.
DR   PANTHER; PTHR10836:SF111; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; 1.
DR   Pfam; PF02800; Gp_dh_C; 1.
DR   Pfam; PF00044; Gp_dh_N; 1.
DR   PIRSF; PIRSF000149; GAP_DH; 1.
DR   PRINTS; PR00078; G3PDHDRGNASE.
DR   SMART; SM00846; Gp_dh_N; 1.
DR   SUPFAM; SSF55347; Glyceraldehyde-3-phosphate dehydrogenase-like, C-terminal domain; 1.
DR   SUPFAM; SSF51735; NAD(P)-binding Rossmann-fold domains; 1.
DR   PROSITE; PS00071; GAPDH; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; ADP-ribosylation; Alternative splicing;
KW   Apoptosis; Cytoplasm; Cytoskeleton; Direct protein sequencing; Glycolysis;
KW   Glycoprotein; Immunity; Innate immunity; Isopeptide bond; Membrane;
KW   Methylation; NAD; Nucleus; Oxidation; Oxidoreductase; Phosphoprotein;
KW   Proteomics identification; Reference proteome; S-nitrosylation;
KW   Transferase; Translation regulation; Ubl conjugation.
FT   INIT_MET        1
FT                   /note="Removed"
FT                   /evidence="ECO:0000269|PubMed:12665801, ECO:0000269|Ref.19"
FT   CHAIN           2..335
FT                   /note="Glyceraldehyde-3-phosphate dehydrogenase"
FT                   /id="PRO_0000145486"
FT   REGION          2..148
FT                   /note="Interaction with WARS1"
FT                   /evidence="ECO:0000269|PubMed:15628863"
FT   MOTIF           245..250
FT                   /note="[IL]-x-C-x-x-[DE] motif"
FT                   /evidence="ECO:0000305|PubMed:25417112"
FT   ACT_SITE        152
FT                   /note="Nucleophile"
FT                   /evidence="ECO:0000269|PubMed:25086035"
FT   BINDING         13..14
FT                   /ligand="NAD(+)"
FT                   /ligand_id="ChEBI:CHEBI:57540"
FT                   /evidence="ECO:0000269|PubMed:16239728,
FT                   ECO:0000269|PubMed:16510976"
FT   BINDING         35
FT                   /ligand="NAD(+)"
FT                   /ligand_id="ChEBI:CHEBI:57540"
FT                   /evidence="ECO:0000269|PubMed:16239728,
FT                   ECO:0000269|PubMed:16510976"
FT   BINDING         80
FT                   /ligand="NAD(+)"
FT                   /ligand_id="ChEBI:CHEBI:57540"
FT                   /evidence="ECO:0000269|PubMed:16239728,
FT                   ECO:0000269|PubMed:16510976"
FT   BINDING         122
FT                   /ligand="NAD(+)"
FT                   /ligand_id="ChEBI:CHEBI:57540"
FT                   /evidence="ECO:0000269|PubMed:16239728,
FT                   ECO:0000269|PubMed:16510976"
FT   BINDING         151..153
FT                   /ligand="D-glyceraldehyde 3-phosphate"
FT                   /ligand_id="ChEBI:CHEBI:59776"
FT                   /evidence="ECO:0000250|UniProtKB:P22513"
FT   BINDING         182
FT                   /ligand="D-glyceraldehyde 3-phosphate"
FT                   /ligand_id="ChEBI:CHEBI:59776"
FT                   /evidence="ECO:0000250|UniProtKB:P22513"
FT   BINDING         211..212
FT                   /ligand="D-glyceraldehyde 3-phosphate"
FT                   /ligand_id="ChEBI:CHEBI:59776"
FT                   /evidence="ECO:0000250|UniProtKB:P22513"
FT   BINDING         234
FT                   /ligand="D-glyceraldehyde 3-phosphate"
FT                   /ligand_id="ChEBI:CHEBI:59776"
FT                   /evidence="ECO:0000250|UniProtKB:P22513"
FT   BINDING         316
FT                   /ligand="NAD(+)"
FT                   /ligand_id="ChEBI:CHEBI:57540"
FT                   /evidence="ECO:0000269|PubMed:16239728,
FT                   ECO:0000269|PubMed:16510976"
FT   SITE            179
FT                   /note="Activates thiol group during catalysis"
FT                   /evidence="ECO:0000305|PubMed:16239728,
FT                   ECO:0000305|PubMed:16510976"
FT   MOD_RES         5
FT                   /note="N6,N6-dimethyllysine"
FT                   /evidence="ECO:0000269|PubMed:18183946"
FT   MOD_RES         9
FT                   /note="Deamidated asparagine"
FT                   /evidence="ECO:0000269|PubMed:18183946"
FT   MOD_RES         42
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0007744|PubMed:15592455"
FT   MOD_RES         46
FT                   /note="Methionine sulfoxide; in vitro"
FT                   /evidence="ECO:0000305|PubMed:25086035"
FT   MOD_RES         61
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         64
FT                   /note="Deamidated asparagine"
FT                   /evidence="ECO:0000269|PubMed:18183946"
FT   MOD_RES         66
FT                   /note="N6,N6-dimethyllysine"
FT                   /evidence="ECO:0000269|PubMed:18183946"
FT   MOD_RES         70
FT                   /note="Deamidated asparagine"
FT                   /evidence="ECO:0000269|PubMed:18183946"
FT   MOD_RES         75
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000269|PubMed:18183946,
FT                   ECO:0007744|PubMed:20068231"
FT   MOD_RES         83
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17081983,
FT                   ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163"
FT   MOD_RES         122
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:18183946"
FT   MOD_RES         148
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:18183946"
FT   MOD_RES         149
FT                   /note="Deamidated asparagine"
FT                   /evidence="ECO:0000269|PubMed:18183946"
FT   MOD_RES         151
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         152
FT                   /note="ADP-ribosylcysteine; by autocatalysis; in
FT                   irreversibly inhibited form"
FT                   /evidence="ECO:0000250|UniProtKB:P04797"
FT   MOD_RES         152
FT                   /note="Cysteine persulfide"
FT                   /evidence="ECO:0000250|UniProtKB:P16858"
FT   MOD_RES         152
FT                   /note="S-(2-succinyl)cysteine"
FT                   /evidence="ECO:0000250|UniProtKB:P04797"
FT   MOD_RES         152
FT                   /note="S-nitrosocysteine; in reversibly inhibited form"
FT                   /evidence="ECO:0000250|UniProtKB:P04797"
FT   MOD_RES         153
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         155
FT                   /note="Deamidated asparagine"
FT                   /evidence="ECO:0000269|PubMed:18183946"
FT   MOD_RES         177
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   MOD_RES         182
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   MOD_RES         184
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:24275569"
FT   MOD_RES         194
FT                   /note="N6,N6-dimethyllysine; alternate"
FT                   /evidence="ECO:0000269|PubMed:18183946"
FT   MOD_RES         194
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         194
FT                   /note="N6-malonyllysine; alternate"
FT                   /evidence="ECO:0000269|PubMed:21908771"
FT   MOD_RES         211
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:19690332"
FT   MOD_RES         215
FT                   /note="N6,N6-dimethyllysine; alternate"
FT                   /evidence="ECO:0000269|PubMed:18183946"
FT   MOD_RES         215
FT                   /note="N6-malonyllysine; alternate"
FT                   /evidence="ECO:0000269|PubMed:21908771"
FT   MOD_RES         219
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         225
FT                   /note="Deamidated asparagine"
FT                   /evidence="ECO:0000269|PubMed:18183946"
FT   MOD_RES         227
FT                   /note="N6,N6-dimethyllysine; alternate"
FT                   /evidence="ECO:0000269|PubMed:18183946"
FT   MOD_RES         227
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         229
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000269|PubMed:18183946,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         237
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000269|PubMed:18183946"
FT   MOD_RES         241
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   MOD_RES         247
FT                   /note="S-(2-succinyl)cysteine"
FT                   /evidence="ECO:0000250|UniProtKB:P04797"
FT   MOD_RES         247
FT                   /note="S-nitrosocysteine"
FT                   /evidence="ECO:0000269|PubMed:22771119,
FT                   ECO:0000269|PubMed:25417112"
FT   MOD_RES         254
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         260
FT                   /note="N6,N6-dimethyllysine"
FT                   /evidence="ECO:0000269|PubMed:18183946"
FT   MOD_RES         263
FT                   /note="N6,N6-dimethyllysine"
FT                   /evidence="ECO:0000269|PubMed:18183946"
FT   MOD_RES         312
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:18183946,
FT                   ECO:0007744|PubMed:19690332"
FT   MOD_RES         316
FT                   /note="Deamidated asparagine"
FT                   /evidence="ECO:0000269|PubMed:18183946"
FT   MOD_RES         333
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         334
FT                   /note="N6,N6-dimethyllysine"
FT                   /evidence="ECO:0000269|PubMed:18183946"
FT   CARBOHYD        197
FT                   /note="(Microbial infection) N-beta-linked (GlcNAc)
FT                   arginine"
FT                   /evidence="ECO:0000269|PubMed:28522607"
FT   CARBOHYD        200
FT                   /note="(Microbial infection) N-beta-linked (GlcNAc)
FT                   arginine"
FT                   /evidence="ECO:0000269|PubMed:28522607"
FT   CROSSLNK        186
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   VAR_SEQ         1..42
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_047289"
FT   VARIANT         22
FT                   /note="A -> G (in dbSNP:rs45541435)"
FT                   /evidence="ECO:0000269|Ref.12"
FT                   /id="VAR_018889"
FT   VARIANT         251
FT                   /note="K -> N (in dbSNP:rs1062429)"
FT                   /id="VAR_049218"
FT   MUTAGEN         46
FT                   /note="M->L: Drastic reduction of the extent and
FT                   significant prolongation of the lag phase of free
FT                   radical-induced aggregation."
FT                   /evidence="ECO:0000269|PubMed:25086035"
FT   MUTAGEN         105
FT                   /note="M->L: Increased resistance to free radical-induced
FT                   aggregation."
FT                   /evidence="ECO:0000269|PubMed:25086035"
FT   MUTAGEN         152
FT                   /note="C->S: Markedly reduced glycolytic activity; when
FT                   associated with S-156 and S-247. Forms free radical-induced
FT                   aggregates, but to a lesser extent than wild-type protein;
FT                   when associated with S-156 and S-247. Abolished interaction
FT                   with TRAF2 and TRAF3."
FT                   /evidence="ECO:0000269|PubMed:23332158,
FT                   ECO:0000269|PubMed:25086035, ECO:0000269|PubMed:27387501"
FT   MUTAGEN         156
FT                   /note="C->S: Markedly reduced glycolytic activity; when
FT                   associated with S-152 and S-247. Forms free radical-induced
FT                   aggregates, but to a lesser extent than wild-type protein;
FT                   when associated with S-156 and S-247."
FT                   /evidence="ECO:0000269|PubMed:25086035"
FT   MUTAGEN         196
FT                   /note="W->F: Increased free radical-induced aggregation."
FT                   /evidence="ECO:0000269|PubMed:25086035"
FT   MUTAGEN         211
FT                   /note="T->A: Does not affect glycosylation by C.rodentium
FT                   protein NleB."
FT                   /evidence="ECO:0000269|PubMed:23332158"
FT   MUTAGEN         229
FT                   /note="T->A: Does not affect glycosylation by C.rodentium
FT                   protein NleB."
FT                   /evidence="ECO:0000269|PubMed:23332158"
FT   MUTAGEN         241
FT                   /note="S->A: Does not affect glycosylation by C.rodentium
FT                   protein NleB."
FT                   /evidence="ECO:0000269|PubMed:23332158"
FT   MUTAGEN         245
FT                   /note="L->M: Inhibits S-nitrosylation of Cys-247; when
FT                   associated with M-250."
FT                   /evidence="ECO:0000269|PubMed:25417112"
FT   MUTAGEN         246
FT                   /note="T->A: Does not affect glycosylation by C.rodentium
FT                   protein NleB."
FT                   /evidence="ECO:0000269|PubMed:23332158"
FT   MUTAGEN         247
FT                   /note="C->S: Markedly reduced glycolytic activity; when
FT                   associated with S-152 and S-156. Forms free radical-induced
FT                   aggregates, but to a lesser extent than wild-type protein;
FT                   when associated with S-156 and S-247."
FT                   /evidence="ECO:0000269|PubMed:25086035"
FT   MUTAGEN         250
FT                   /note="E->M: Inhibits S-nitrosylation of Cys-247; when
FT                   associated with M-245."
FT                   /evidence="ECO:0000269|PubMed:25417112"
FT   MUTAGEN         277
FT                   /note="T->A: Does not affect glycosylation by C.rodentium
FT                   protein NleB."
FT                   /evidence="ECO:0000269|PubMed:23332158"
FT   MUTAGEN         320
FT                   /note="Y->F: No effect on free radical-induced
FT                   aggregation."
FT                   /evidence="ECO:0000269|PubMed:25086035"
FT   CONFLICT        225
FT                   /note="N -> D (in Ref. 2; CAA25833)"
FT                   /evidence="ECO:0000305"
FT   STRAND          5..9
FT                   /evidence="ECO:0007829|PDB:6YND"
FT   HELIX           13..25
FT                   /evidence="ECO:0007829|PDB:6YND"
FT   STRAND          27..34
FT                   /evidence="ECO:0007829|PDB:6YND"
FT   STRAND          36..38
FT                   /evidence="ECO:0007829|PDB:6YND"
FT   HELIX           40..48
FT                   /evidence="ECO:0007829|PDB:6YND"
FT   TURN            51..53
FT                   /evidence="ECO:0007829|PDB:6YND"
FT   STRAND          60..63
FT                   /evidence="ECO:0007829|PDB:6YND"
FT   STRAND          66..69
FT                   /evidence="ECO:0007829|PDB:6YND"
FT   STRAND          72..77
FT                   /evidence="ECO:0007829|PDB:6YND"
FT   HELIX           82..84
FT                   /evidence="ECO:0007829|PDB:6YND"
FT   HELIX           88..90
FT                   /evidence="ECO:0007829|PDB:6YND"
FT   STRAND          94..97
FT                   /evidence="ECO:0007829|PDB:6YND"
FT   STRAND          99..101
FT                   /evidence="ECO:0007829|PDB:6YND"
FT   HELIX           105..108
FT                   /evidence="ECO:0007829|PDB:6YND"
FT   HELIX           110..113
FT                   /evidence="ECO:0007829|PDB:6YND"
FT   STRAND          117..123
FT                   /evidence="ECO:0007829|PDB:6YND"
FT   STRAND          126..128
FT                   /evidence="ECO:0007829|PDB:6YND"
FT   TURN            133..135
FT                   /evidence="ECO:0007829|PDB:6YND"
FT   HELIX           137..139
FT                   /evidence="ECO:0007829|PDB:6YND"
FT   STRAND          146..148
FT                   /evidence="ECO:0007829|PDB:6YND"
FT   HELIX           152..168
FT                   /evidence="ECO:0007829|PDB:6YND"
FT   STRAND          170..179
FT                   /evidence="ECO:0007829|PDB:6YND"
FT   STRAND          185..189
FT                   /evidence="ECO:0007829|PDB:6YND"
FT   HELIX           196..199
FT                   /evidence="ECO:0007829|PDB:6YND"
FT   TURN            202..204
FT                   /evidence="ECO:0007829|PDB:6YND"
FT   STRAND          207..210
FT                   /evidence="ECO:0007829|PDB:6YND"
FT   HELIX           213..220
FT                   /evidence="ECO:0007829|PDB:6YND"
FT   HELIX           222..224
FT                   /evidence="ECO:0007829|PDB:6YND"
FT   STRAND          227..234
FT                   /evidence="ECO:0007829|PDB:6YND"
FT   STRAND          241..251
FT                   /evidence="ECO:0007829|PDB:6YND"
FT   HELIX           255..267
FT                   /evidence="ECO:0007829|PDB:6YND"
FT   TURN            268..273
FT                   /evidence="ECO:0007829|PDB:6YND"
FT   STRAND          274..277
FT                   /evidence="ECO:0007829|PDB:6YND"
FT   HELIX           283..286
FT                   /evidence="ECO:0007829|PDB:6YND"
FT   STRAND          292..296
FT                   /evidence="ECO:0007829|PDB:6YND"
FT   TURN            297..299
FT                   /evidence="ECO:0007829|PDB:6YND"
FT   STRAND          301..304
FT                   /evidence="ECO:0007829|PDB:6YND"
FT   STRAND          307..314
FT                   /evidence="ECO:0007829|PDB:6YND"
FT   HELIX           318..333
FT                   /evidence="ECO:0007829|PDB:6YND"
SQ   SEQUENCE   335 AA;  36053 MW;  C9C135E8AE3E8744 CRC64;
     MGKVKVGVNG FGRIGRLVTR AAFNSGKVDI VAINDPFIDL NYMVYMFQYD STHGKFHGTV
     KAENGKLVIN GNPITIFQER DPSKIKWGDA GAEYVVESTG VFTTMEKAGA HLQGGAKRVI
     ISAPSADAPM FVMGVNHEKY DNSLKIISNA SCTTNCLAPL AKVIHDNFGI VEGLMTTVHA
     ITATQKTVDG PSGKLWRDGR GALQNIIPAS TGAAKAVGKV IPELNGKLTG MAFRVPTANV
     SVVDLTCRLE KPAKYDDIKK VVKQASEGPL KGILGYTEHQ VVSSDFNSDT HSSTFDAGAG
     IALNDHFVKL ISWYDNEFGY SNRVVDLMAH MASKE
//
